BTK Inhibitors as Sensitizing Agents in Solid Tumors

Robert Dreicer, MD, MS, FASCO, MACP received his medical degree from the University of Texas-Houston and a Master of Science from the University of Texas Graduate School of Biomedical Sciences. Following his oncology fellowship, he joined the faculty at University of Iowa, achieving tenure and serving as the associate director of the division of haematology/oncology. He was recruited to Cleveland Clinic, where he served as chair of the department of solid tumor oncology from 2006-2014, before joining UVA Cancer Center in 2015. His research interests are in novel therapeutic approaches for urologic cancer including prostate, urothelial and kidney cancers. He serves as member of the Medical Oncology Test Writing Committee of the American Board of Internal Medicine and is member of the editorial board of New England Journal of Medicine's Journal Watch Hematology/Oncology. Dreicer has been named for many years to Top Doctors in America, America’s Best Doctors and America’s Top Doctors for Cancer. Dr Varinder Kaur MD, FACP has expertise in haematology and medical oncology, including clinical application of ibrutinib in its varied roles. She is a clinical trialist at University of Virginia, with particular focus on melanoma and head-neck cancers, immune-oncology, and vaccine trials. She has authored several high-quality publications including with rare side effects and resistance mechanisms for ibrutinib. She mentors clinical fellows and residents. She is a member of scientific review committee of Oncology Research Information Exchange Network and has reviewed grant applications for the same. She has served as a member for American Society of Clinical Oncology Systemic Therapy guidelines for melanoma committee and ASCO/ABIM test material development subcommittee, as well as a member of ASCO Education Book Review Panel. Dr. Al-Ola Abdallah MD is currently Assistant Professor of Medicine and the director of the Plasma Cell Disorder Clinic for the Division of Hematological Malignancies and Cellular Therapy (HMCT). Recently he was also appointed as the Educational Medical Director for the Division. Dr. Abdallah currently works as principal investigator on many investigator-initiated and pharmaceutical-sponsored clinical trials. His research interests include multiple myeloma, smoldering myeloma, amyloidosis, immunotherapy and CAR-T cell for myeloma and CLL, with a focus on improving patient outcomes specifically patients with high-risk subsets of plasma cell dyscrasias and health- related quality of life in myeloma patients.

• 1. Overview of BTK pathway2. Overview of BTK inhibitors and their clinical utility [1st gen, 2nd gen]3. Mechanisms of therapy resistance in cancer cells4. BTK inhibitors in paclitaxel and docetaxel resistance5. BTK inhibitors in Platinum resistance6. BTK inhibitors in BRAF resistance7. BTK inhibitors in radio-resistance8. Ibrutinib beyond BTK inhibition and role in immunotherapy resistance9. Novel BTK inhibitors and future perspectives